Condition: Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: New Cancer Cure-Bio Co.,Ltd.
This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).
This description comes directly from the study's public registry record.
Joon Hee Kang, Ph.D · +8231-920-2227 · wnsl2820@gmail.com
Always discuss trial participation with your own doctor first.
| National Cancer Center | Goyang-si, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07114861